Am J Transl Res 2024;16(12):8083-8086
www.ajtr.org /ISSN:1943-8141/AJTR0139694

Erratum
CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT: Am J Transl Res. 2018; 10(1): 274-282

Ke Cao[1*], Minhuan Li[2*], Ji Miao[1*], Xiaofeng Lu[1], Xing Kang[1], Hao Zhu[3], Shangce Du[1], Xue Li[1], Qian Zhang[1], Wenxian Guan[1], Ying Dong[4], Xuefeng Xia[1]

[1]Department of General Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China; [2]Department of Laboratory Medicine, Sir Run RunHospital, Nanjing Medical University, Nanjing 210000, Jiangsu, China; [3]Department of Gastroenterology, The Afflicted Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, Jiangsu, China; [4]Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China. [*]Equal contributors and co-first authors.

Received October 9, 2021; Accepted August 28, 2024; Epub December 15, 2024; Published December 30, 2024

Two small errors were found in the figures of this paper. The first was in **Figure 1A**: where the cell name "GIIS-882T" was incorrect, and secondly, in **Figure 4C**: the Hoechest 3344 image of the imatinib group in GIST1 cells was not consistent with the EDU and Merge. We revised the cell name "GIIS-882T" to "GIST-882" in **Figure 1A**. We also have accordingly corrected and replaced the panel in **Figure 4C** with the image of Hoechest 3344 of the imatinib group in GIST1 cells. Changes in representative images do not affect the interpretation of **Figure 1A** or **Figure 4C**. These errors have no bearings on the interpretation of the results, nor do they influence the conclusions of the work. We apologize for these mistakes. The corrected figures are as follows.

Address correspondence to: Xuefeng Xia and Wenxian Guan, Department of General Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, No. 321, Zhongshan Road, Nanjing 210008, Jiangsu, China. Tel: +86-025-83106666; Fax: +86-025-83106665; E-mail: 18114483312@sina.cn (XFX); 15850502391@163.com (WXG)

https://doi.org/10.62347/RANJ9550



Figure 1. CCDC26 expression in GIST cells and its relationship with imatinib sensitivity. A: Real-time PCR detection of CCDC26 expression in GIST cell lines. B: CCK-8 assay of GIST cell viability in the presence of imatinib (0, 20, 40, 60, 80 μM). C, D: GIST cell viability in the presence of IC50 of imatinib (GIST-882, 56.06 μM; GIST-T1, 41.08 μM) for 0 h, 6 h, 24 h, and 48 h (**$P < 0.01$).


A
GIST-882
Control
Negative siRNA
C-KIT siRNA
Relative cell viability (% of control)
Imatinib(μM)
B
GIST-T1
Control
Negative siRNA
C-KIT siRNA
Relative cell viability (% of control)
Imatinib(μM)
C
GIST-T1
EDU
Hoechest 3344
Merge
Imatinib
siRNA+Imatinib
GIST-T1
EDU-positive cell ratio(%)
Imatinib
siRNA+Imatinib
D
GIST-882
EDU
Hoechest 3344
Merge
Imatinib
siRNA+Imatinib
GIST-882
EDU-positive cell ratio(%)
Imatinib
siRNA+Imatinib



Figure 4. Effect of c-KIT on GIST cell viability, proliferation, and apoptosis *in vitro*. A, B: CCK-8 assay of the viability of GIST cells treated with c-KIT siRNA, Negative siRNA, or Control in the presence of imatinib (0, 20, 40, 60, 80 μM). C, D: EdU assay of cell proliferation rate under IC50 of imatinib in GIST cells treated with c-KIT siRNA or control siRNA. The number of EDU-positive cells was counted. E: Flow cytometry analysis of apoptosis in GIST cells transfected with control siRNA or CCDC26 siRNA (*$P < 0.05$).